Marc Lemonnier

Ph.D., co-founder, CEO, is an entrepreneurial scientist with a deep knowledge of pathogenic bacterial infections and their biology. Marc holds a PhD in Microbiology from the University of Toulouse (France). He has carried out his research and bioentrepreneurial activities in an international context from Toulouse to New York City and has worked for and managed collaborations with major research institutions in Europe and the US (French CNRS and INSERM, CSIC Spain, Emory University in Atlanta GA). Marc is the author of numerous peer-reviewed articles in the antibacterial field and the inventor of ANTABIO’s technology.

Aymeric Dugray

Ph.D., co-founder, CFO, has both a business and scientific background. He has a Specialized Master of Entrepreneurship from ESCP-Europe. After co-founding and acting as CEO of Nokad®, a biotech CRO, he became the COO of Wittycell, a biotech company focused on the development of innovative vaccine adjuvants. He created and led two biotech specific entities that enabled young start-ups to share their employees and their professional networks. During these years, Aymeric has acquired expertise in the creation and management of innovative projects in the field of Biotechnology.

Delphine Ortega

MBA, International project manager & Business Developer, has both a scientific and business background (Biotech Engineer & Master of Global Innovation Management). Before joining ANTABIO, Delphine worked as a project manager at Neuroservice, a french CRO specialized in CNS safety, and later as a San Francisco-based Biotech Trade Advisor for Ubifrance, the French Agency for International Business Development. Delphine was responsible for organizing and managing multiple international partnering events involving biopharmaceutical companies of both sides of the Atlantic, from small start-up companies and bio-clusters to the top 10 players in the pharmaceutical industry.